Phaseline

Companies › Eli Lilly

Eli Lilly: clinical trials, targets and expected readouts

91 active drug programs in 458 registered trials: 187 Phase 2, 118 Phase 3, 106 Phase 1, 47 Phase 4; Oncology, Metabolic and endocrine, Other, Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Tirzepatide (LY3298176)
Gastric inhibitory polypeptide receptor agonist; Glucagon-like peptide 1 receptor agonist
GIPR, GLP1RPhase 4Diabetes Mellitus, Type 2; Psoriatic Arthritis; Type 2 Diabetes; Psoriasis …Nov 2026
Lebrikizumab (LY3650150)
Interleukin-13 inhibitor
IL13Phase 4Atopic Dermatitis; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Perennial Allergic Rhinitis (PAR)Dec 2026
Mirikizumab (LY3074828)
Interleukin-23 inhibitor
IL12B, IL23APhase 4Lactation; Crohn's Disease; Ulcerative Colitis; Colitis, Ulcerative …Feb 2027
Pirtobrutinib (LY3527727)
Tyrosine-protein kinase BTK inhibitor
BTKPhase 4Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Immune Thrombocytopenia (ITP)Feb 2028
Abemaciclib (LY2835219)
Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor
CDK4, CDK6Phase 3Non Small Cell Lung Cancer; Breast Cancer; Breast Neoplasms; Prostatic Neoplasms …Nov 2026
Brenipatide (LY3537031)
GLP-1 receptor agonist
GLP1RPhase 3Depressive Disorder, Major; Alcohol Use Disorder; Smoking; Irritable Bowel Syndrome …Nov 2026
Galcanezumab (LY2951742)
Calcitonin gene-related peptide inhibitor
CALCA, CALCBPhase 3Episodic Migraine; Chronic MigraineNov 2026
Retatrutide
Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist
GCGR, GLP1R, GIPRPhase 3Obesity; Type 2 Diabetes; Diabetes Mellitus, Type 2; Atherosclerotic Cardiovascular Disease (ASCVD) …Nov 2026
Eloralintide (LY3841136)
GLP-1/GCG dual receptor agonist
GLP1R, GCGRPhase 3Overweight; Obesity; Sleep Apnea, Obstructive; Osteoarthritis …Dec 2026
Imlunestrant (LY3484356)
Selective estrogen receptor degrader (SERD)
ESR1Phase 3Breast Neoplasms; Breast Cancer; Anatomic Stage I Breast Cancer AJCC v8Dec 2026
Ramucirumab (LY3009806)
Vascular endothelial growth factor receptor 2 inhibitor
KDRPhase 3Metastatic Non-Small Cell Lung Cancer; Biliary Tract Cancer; Neoplasms; Recurrent Lung Non-Small Cell Carcinoma …Dec 2026
Orforglipron (LY3502970)
GLP-1 receptor agonist
GLP1RPhase 3Obesity; Diabetes Mellitus, Type 2; Hypertension; Urinary Incontinence,Stress …Feb 2027
Selpercatinib
Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
RET, KIF5B, CCDC6Phase 3Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Solid Tumor; Medullary Thyroid Cancer …Feb 2027
Olomorasib (LY3537982)
KRAS G12C inhibitor
KRASPhase 3Carcinoma, Non-Small-Cell Lung; Healthy VolunteersApr 2027
Donanemab (LY3002813)
Amyloid-beta A4 protein disrupting agent
APPPhase 3Alzheimer's Disease; Alzheimer Disease; Cognitive Dysfunction; Autosomal Dominant Alzheimers DiseaseMay 2027
Pirtobrutinib
Tyrosine-protein kinase BTK inhibitor
BTKPhase 3Chronic Lymphocytic Leukemia; Lymphoma, Mantle-Cell; Richter Syndrome; Mantle Cell Lymphoma …May 2027
Vepugratinib (LY3866288)
FGFR3 inhibitor
FGFR3Phase 3Carcinoma, Transitional Cell; Urinary Bladder NeoplasmsJun 2027
Selpercatinib (LY3527723)
Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
RET, KIF5B, CCDC6Phase 3Medullary Thyroid CancerNov 2027
Dulaglutide (LY2189265)
Glucagon-like peptide 1 receptor agonist
GLP1RPhase 3Type 2 Diabetes; Myocardial Injury; Cystic Fibrosis; Diabetes Mellitus, Type 1 …Dec 2027
Baricitinib (LY3009104)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor
JAK1, JAK2Phase 3Systemic Juvenile Idiopathic Arthritis; Areata Alopecia; Diabetes Mellitus, Type 1; Uveitis …Mar 2028
AAVAnc80-hOTOF
Adeno-associated virus serotype delivering functional otoferlin gene
OTOFPhase 3Sensorineural Hearing Loss, BilateralOct 2028
Sofetabart Mipitecan (Sofe-M, LY4170156)–Phase 3Ovarian NeoplasmsNov 2028
Ixekizumab (LY2439821)
Interleukin 17A inhibitor
IL17APhase 3Juvenile Psoriatic Arthritis; Plaque Psoriasis; Psoriasis Vulgaris; Type1 Diabetes MellitusJan 2029
Lepodisiran Sodium
Lipoprotein(a) synthesis inhibitor (antisense oligonucleotide)
LPAPhase 3Atherosclerotic Cardiovascular Disease (ASCVD); AtherosclerosisMar 2029
Remternetug (LY3372993)
LRRK2 inhibitor
LRRK2Phase 3Alzheimer's Disease; Alzheimers DiseaseApr 2029
Tersolisib (LY4064809/STX-478)
PIK3CA inhibitor
PIK3CAPhase 3Breast NeoplasmsMay 2029
Muvalaplin (LY3473329)
Lipoprotein(a) biosynthesis inhibitor
APOAPhase 3Elevated Lp(a)Mar 2031
LY3938577
GLP-1 receptor agonist
GLP1RPhase 2Diabetes Mellitus, Type 2Nov 2026
LY4515100–Phase 2Acute Pain; HealthyNov 2026
LY2784544
JAK inhibitor
JAKPhase 2Neoplasms, HematologicDec 2026
LY3537021
NK1 receptor antagonist
–Phase 2NauseaDec 2026
Merestinib (LY2801653)
Hepatocyte growth factor receptor inhibitor
METPhase 2Biliary Tract CancerDec 2026
Bimagrumab (LY3985863)
Activin receptor type-2B antagonist
ACVR2BPhase 2ObesityJan 2027
Macupatide (LY3532226)
Amylin receptor agonist
CALCRPhase 2Obesity; OverweightMar 2027
Solbinsiran (LY3561774)
Antisense oligonucleotide targeting APOC3 mRNA, reducing apoC-III levels and triglycerides
APOC3Phase 2Severe HypertriglyceridemiaMar 2027
LY3016859–Phase 2Osteoarthritis, KneeApr 2027
LY3526318–Phase 2Osteoarthritis, KneeApr 2027
LY3556050–Phase 2Osteoarthritis, KneeApr 2027
LY3857210–Phase 2Osteoarthritis, KneeApr 2027
LY4065967–Phase 2Osteoarthritis, Knee; Chronic Pain; Diabetic Peripheral Neuropathic PainApr 2027
Clazakizumab (LY5724886)
Interleukin-6 inhibitor
IL6Phase 2AtherosclerosisMay 2027
LY3457263–Phase 2Type 2 DiabetesMay 2027
LY4005130–Phase 2Vitiligo; Alopecia AreataMay 2027
LY4268989–Phase 2Ulcerative Colitis; Ulcerative Colitis (UC); HealthyMay 2027
LY4395089
Farnesoid X receptor (FXR) agonist
NR1H4Phase 2Colitis, Ulcerative; Crohn DiseaseJun 2027
Eltrekibart
OX40 agonist
OX40Phase 2Ulcerative ColitisJul 2027
LY3305677–Phase 2ObesitySep 2027
LY3549492–Phase 2ObesitySep 2027
LOXO-783
PIK3CA inhibitor
PIK3CAPhase 1Breast CancerDec 2026
LY4167586
unclear - GLP-1 receptor agonist (suspected based on indication and Eli Lilly pipeline)
–Phase 1OverweightDec 2026
Samotolisib (LY3023414)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 1Breast Neoplasms; Endometrial CancerDec 2026
LY4355756–Phase 1HealthyJan 2027
LY3981314–Phase 1HealthyFeb 2027
LY4057996
GLP-1 receptor agonist
–Phase 1Diabetes Mellitus, Type 1Mar 2027
LY4101174–Phase 1Metastatic Solid TumorMar 2027
LY4152199–Phase 1Lymphoma, Non-HodgkinApr 2027
LY3410738
Covalent isocitrate dehydrogenase (IDH) inhibitor
IDH1, IDH2Phase 1Acute Myeloid Leukemia (AML); CholangiocarcinomaMay 2027
LY4052031–Phase 1Metastatic Solid TumorMay 2027
LY4006895–Phase 1Alzheimer DiseaseJul 2027
LY4088044–Phase 1HealthyJul 2027
LY4226695–Phase 1HealthyJul 2027
LY3200882–Phase 1Solid TumorAug 2027
LY3295668 Erbumine–Phase 1NeuroblastomaAug 2027
LY3300054–Phase 1Solid TumorAug 2027
LY3439539–Phase 1Alzheimer DiseaseAug 2027
LY4256984–Phase 1ALS (Amyotrophic Lateral Sclerosis); Amyotrophic Lateral SclerosisAug 2027
LY4302814–Phase 1HealthyAug 2027
LY5625575–Phase 1Healthy VolunteersAug 2027
LY4066708–Phase 1HealthySep 2027
LY4329090
GLP-1 receptor agonist
–Phase 1ObesitySep 2027
[Ac-225]-PSMA-62
Actinium-225 labeled anti-PSMA targeted alpha particle therapy
PSMAPhase 1Prostate CancerSep 2027
LY4050784
SMARCA4/BRG1 inhibitor
SMARCA4Phase 1Metastatic Solid TumorOct 2027
LY3971297–Phase 1Heart FailureNov 2027
[18F]LY4214835
Positron emission tomography (PET) imaging agent
–Phase 1NeoplasmsDec 2027
LY4405094
Amyloid-targeting therapy
–Phase 1Healthy Volunteers; Alzheimer DiseaseJan 2028
LY3962673
KRAS G12D inhibitor
KRASPhase 1Pancreatic Ductal AdenocarcinomaMar 2028
LY4178256–Phase 1Healthy VolunteersMar 2028
LY4213663–Phase 1Rheumatoid Arthritis (RA)Mar 2028
LY4298445–Phase 1HealthyMar 2028
LY3954068
LRRK2 inhibitor
–Phase 1Alzheimer DiseaseJul 2028
LY4337713
FAP-targeting antibody-drug conjugate
–Phase 1Ovarian NeoplasmsJul 2028
LY4584180–Phase 1Lymphoma, Non-Hodgkin'sSep 2028
LY4006896–Phase 1Parkinson DiseaseOct 2028
LY4174794–Phase 1ObesityApr 2029
AAVAnc80-antiVEGF
AAV-mediated anti-VEGF gene therapy
VEGFAPhase 1Vestibular SchwannomaAug 2029
LY4066434
Pan-KRAS inhibitor
KRASPhase 1Pancreatic Ductal AdenocarcinomaJan 2030
LY4257496
GRPR-targeting therapeutic (mechanism to be determined in Phase 1)
GRPRPhase 1Breast NeoplasmsApr 2030
LY4175408
unclear - mechanism not stated
–Phase 1Carcinoma, Non-Small-Cell LungJul 2030
STX-478
mutant-selective PI3Kα inhibitor
PIK3CAPhase 1Breast CancerJul 2030
LY3867070–Phase 1Healthy–
Tersolisib (LY4064809)
PI3K inhibitor
PIK3CAPhase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02747004Abemaciclib (LY2835219)Phase 2Metastatic Breast CancerOncologyJun 2018
NCT06936215Baricitinib (LY3009104)Phase 3Diffuse Cutaneous Systemic SclerosisImmunologyMay 2025
NCT06768840Baricitinib (LY3009104)Phase 2Vitiligo, GeneralizedImmunologyAug 2025
NCT06280716Lebrikizumab (LY3650150)Phase 3Atopic DermatitisImmunologySep 2025
NCT03891784Abemaciclib (LY2835219)Phase 2Advanced Digestive System Neuroendocrine NeoplasmOncologyNov 2025
NCT05894824Ramucirumab (LY3009806)Phase 1Gastric CancerOncologyDec 2025
NCT06037252Tirzepatide (LY3298176)Phase 2Type 2 DiabetesMetabolic and endocrineJan 2026
NCT05955066Baricitinib (LY3009104)Phase 4Rheumatoid ArthritisImmunologyFeb 2026
NCT07006792Lebrikizumab (LY3650150)Phase 4Atopic DermatitisImmunologyMay 2026
NCT06630585Tirzepatide (LY3298176)Phase 3Type 1 Diabetes (T1D)Metabolic and endocrineJun 2026
NCT06918405Tirzepatide (LY3298176)Phase 3Obesity and Obesity-related Medical ConditionsMetabolic and endocrineJun 2026
NCT06603571Eloralintide (LY3841136)Phase 2ObesityMetabolic and endocrineJul 2026
NCT06603571Tirzepatide (LY3298176)Phase 2ObesityMetabolic and endocrineJul 2026
NCT07423247Tirzepatide (LY3298176)Phase 4TirzepatideOtherJul 2026
NCT06994338Tirzepatide (LY3298176)Phase 2Alcohol Use DisorderMetabolic and endocrineAug 2026
NCT07662798Tersolisib (LY4064809)Phase 1HealthyOtherSep 2026
NCT07021547LY3867070Phase 1HealthyOtherSep 2026
NCT07707375LY4268989Phase 1HealthyOtherOct 2026
NCT07701083Eloralintide (LY3841136)Phase 1Healthy VolunteersOtherOct 2026
NCT07426380Eloralintide (LY3841136)Phase 1Kidney DiseaseGenitourinaryOct 2026
NCT04088396Baricitinib (LY3009104)Phase 3Systemic Juvenile Idiopathic ArthritisImmunologyOct 2026
NCT07794592Olomorasib (LY3537982)Phase 1Healthy VolunteersOtherOct 2026
NCT05677919PirtobrutinibPhase 2Chronic Lymphocytic LeukemiaOncologyNov 2026
NCT05300932Baricitinib (LY3009104)Phase 4Systemic SclerosisImmunologyNov 2026
NCT06662383RetatrutidePhase 3ObesityMetabolic and endocrineNov 2026
NCT06297603RetatrutidePhase 3Type 2 DiabetesMetabolic and endocrineNov 2026
NCT07818967Abemaciclib (LY2835219)Phase 1Healthy VolunteersOtherNov 2026
NCT06962280Tirzepatide (LY3298176)Phase 3Type 1 DiabetesMetabolic and endocrineNov 2026
NCT06914895Tirzepatide (LY3298176)Phase 3Type 1 DiabetesMetabolic and endocrineNov 2026
NCT07299084Tirzepatide (LY3298176)Phase 1Diabetes Mellitus, Type 2Metabolic and endocrineNov 2026
NCT07165002Brenipatide (LY3537031)Phase 1HealthyGastroenterologyNov 2026
NCT06606106Brenipatide (LY3537031)Phase 1OverweightMetabolic and endocrineNov 2026
NCT03432286Galcanezumab (LY2951742)Phase 3Episodic MigraineNeurologyNov 2026
NCT07511816LY4515100Phase 2Acute PainOtherNov 2026
NCT07215312LY3938577Phase 2Diabetes Mellitus, Type 2Metabolic and endocrineNov 2026
NCT04660760Ramucirumab (LY3009806)Phase 2Clinical Stage III Gastric Cancer AJCC v8OncologyNov 2026
NCT04545710Abemaciclib (LY2835219)Phase 2Lung CancerOncologyDec 2026
NCT05305924Abemaciclib (LY2835219)Phase 2ER-Positive Breast CancerOncologyDec 2026
NCT04393285Abemaciclib (LY2835219)Phase 2Endometrial CancerOncologyDec 2026
NCT04268550SelpercatinibPhase 2Recurrent Lung Non-Small Cell CarcinomaOncologyDec 2026
NCT05559359Lebrikizumab (LY3650150)Phase 3Atopic DermatitisImmunologyDec 2026
NCT05509790Imlunestrant (LY3484356)Phase 1Breast NeoplasmsOncologyDec 2026
NCT07738614Eloralintide (LY3841136)Phase 1ObesityMetabolic and endocrineDec 2026
NCT02152631Abemaciclib (LY2835219)Phase 3Non Small Cell Lung CancerOncologyDec 2026
NCT02246621Abemaciclib (LY2835219)Phase 3Breast CancerOncologyDec 2026
NCT03706365Abemaciclib (LY2835219)Phase 2Prostate CancerOncologyDec 2026
NCT02779751Abemaciclib (LY2835219)Phase 1Non Small Cell Lung CancerOncologyDec 2026
NCT02057133Abemaciclib (LY2835219)Phase 1Breast NeoplasmsOncologyDec 2026
NCT07803744Tirzepatide (LY3298176)Phase 1Diabetes Mellitus, Type 1Metabolic and endocrineDec 2026
NCT06901245Tirzepatide (LY3298176)Phase 4Prader-Willi SyndromeMetabolic and endocrineDec 2026
NCT07128082Tirzepatide (LY3298176)Phase 2Long COVIDInfectious diseaseDec 2026
NCT01594723LY2784544Phase 2Neoplasms, HematologicOncologyDec 2026
NCT02411448Ramucirumab (LY3009806)Phase 3Metastatic Non-Small Cell Lung CancerOncologyDec 2026
NCT02711553Ramucirumab (LY3009806)Phase 2Biliary Tract CancerOncologyDec 2026
NCT03909334Ramucirumab (LY3009806)Phase 2Non Small Cell Lung CancerOncologyDec 2026
NCT03527108Ramucirumab (LY3009806)Phase 2Non Small Cell Lung CancerOncologyDec 2026
NCT02711553Merestinib (LY2801653)Phase 2Biliary Tract CancerOncologyDec 2026
NCT05307705LOXO-783Phase 1Breast CancerOncologyDec 2026
NCT02057133Samotolisib (LY3023414)Phase 1Breast NeoplasmsOncologyDec 2026
NCT07225556LY4167586Phase 1OverweightMetabolic and endocrineDec 2026

The 60 nearest readouts of 458 trials; the rest in the app.

From the company's SEC filings

Cash of $4.9bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Specialist investors

Held by 7 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

GLP1R (7) PIK3CA (5) KRAS (3) GCGR (2) GIPR (2) BTK (2) RET (2) KIF5B (2) CCDC6 (2) IL13 (1) IDH1 (1) IDH2 (1)

Companies with the same targets

Roche Novo Nordisk Revolution Medicines Novartis AstraZeneca Amgen Boehringer Ingelheim TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Pfizer Hanmi Pharmaceutical Company

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.